Alphabet Inc. holds a concentrated book of 28 stocks worth $99.1B as of Q2 2026 (disclosed Aug 7, 2026, a ~38-day 13F lag). This quarter they opened Space Exploration Techn Corp and trimmed Revolution Medicines Inc. Their largest long position is Space Exploration Techn Corp at 95% of the equity book.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
5% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Alphabet Inc.
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 33 / 28 | $7.8B |
| BlackRock, Inc. | 31 / 28 | $18.1B |
| MORGAN STANLEY | 31 / 28 | $4.7B |
| UBS Group AG | 31 / 28 | $2.7B |
| OSAIC HOLDINGS, INC. | 30 / 28 | $78.1M |
| Integrated Wealth Concepts LLC | 30 / 28 | $24.3M |
| STATE STREET CORP | 29 / 28 | $8.3B |
| Ken Griffin | 29 / 28 | $893.0M |
Ranked by how many of Alphabet Inc.'s top 28 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Space Exploration Techn Corp CLASS A COM STK | $94.2B | 551.19M | 95.0% | ▲New New position | |
| 2 | Planet Labs PBC COM CL A | $1.2B | 35.25M | 1.2% | —Held | |
| 3 | Ast Spacemobile Inc COM CL A | $794.7M | 8.94M | 0.8% | —Held | |
| 4 | Cme Group Inc COM | $769.4M | 3.48M | 0.8% | —Held | |
| 5 | Arm Holdings PLC SPONSORED ADS | $695.2M | 1.96M | 0.7% | —Held | |
| 6 | Revolution Medicines Inc COM | $551.8M | 2.95M | 0.6% | ▼−11% Reduced · −346K sh | |
| 7 | Freshworks Inc CLASS A COM | $164.0M | 16.21M | 0.2% | —Held | |
| 8 | Parabilis Medicines Inc COM | $134.6M | 4.92M | 0.1% | ▲New New position | |
| 9 | Tempus AI Inc CL A | $89.9M | 1.55M | 0.1% | —Held | |
| 10 | Gitlab Inc CLASS A COM | $83.2M | 2.72M | 0.1% | —Held | |
| 11 | Uipath Inc CL A | $76.5M | 7.03M | 0.1% | —Held | |
| 12 | Ethos Technologies Inc CL A | $65.7M | 3.62M | 0.1% | ▼−3.9% Reduced · −148K sh | |
| 13 | Prime Medicine Inc COM | $61.1M | 16.56M | 0.1% | —Held | |
| 14 | Fervo Energy Co CL A COM | $51.5M | 1.76M | 0.1% | ▲New New position | |
| 15 | Paypay Corp SPONSORED ADS | $44.8M | 3.13M | 0.0% | —Held | |
| 16 | Maze Therapeutics Inc COM | $41.4M | 1.39M | 0.0% | —Held | |
| 17 | Relay Therapeutics Inc COM | $26.4M | 1.41M | 0.0% | ▼−9.8% Reduced · −154K sh | |
| 18 | Bridgebio Oncology Therapeut COM NEW | $21.5M | 2.82M | 0.0% | —Held | |
| 19 | Oscar Health Inc CL A | $13.7M | 482.0K | 0.0% | —Held | |
| 20 | Beam Therapeutics Inc COM | $11.0M | 321.6K | 0.0% | —Held | |
| 21 | Vera Therapeutics Inc CL A | $10.4M | 241.3K | 0.0% | —Held | |
| 22 | Sana Biotechnology Inc COM | $9.8M | 2.81M | 0.0% | —Held | |
| 23 | Monte Rosa Therapeutics Inc COM | $9.0M | 372.5K | 0.0% | ▼−46% Reduced · −312K sh | |
| 24 | Lyell Immunopharma Inc COM NEW | $4.1M | 293.3K | 0.0% | —Held | |
| 25 | Figma Inc CLASS A COM STK | $3.9M | 215.6K | 0.0% | —Held | |
| 26 | Spero Therapeutics Inc COM | $2.0M | 890.0K | 0.0% | —Held | |
| 27 | Hyperfine Inc COM CL A | $1.2M | 898.7K | 0.0% | —Held | |
| 28 | Autolus Therapeutics PLC SPON ADS | $1.1M | 698.3K | 0.0% | —Held |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1652044/holdings"
Use Arkolith to show Alphabet Inc.'s latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | Aug 7, 2026 | 29 | $99.1B | 13F-HR |
| Q1 2026 | Mar 31, 2026 | May 8, 2026 | 27 | $4.0B | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 13, 2026 | 32 | $2.6B | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 7, 2025 | 40 | $2.4B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 1, 2025 | 39 | $2.1B | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 2, 2025 | 44 | $1.6B | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 7, 2025 | 44 | $1.7B | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 8, 2024 | 46 | $1.8B | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 2, 2024 | 46 | $2.0B | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 3, 2024 | 47 | $2.5B | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 9, 2024 | 48 | $2.2B | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 13, 2023 | 51 | $1.6B | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Aug 4, 2023 | 56 | $1.9B | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 11, 2023 | 58 | $1.8B | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 14, 2023 | 61 | $1.7B | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 15, 2022 | 59 | $2.0B | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Nov 15, 2022 | 65 | $1.8B | 13F-HR |
| Q1 2022 | Mar 31, 2022 | Nov 15, 2022 | 70 | $3.1B | 13F-HR |
| Q4 2021 | Dec 31, 2021 | Nov 15, 2022 | 67 | $4.1B | 13F-HR |
| Q3 2021 | Sep 30, 2021 | Nov 15, 2022 | 52 | $4.2B | 13F-HR |
| Q2 2021 | Jun 30, 2021 | Nov 15, 2022 | 44 | $4.9B | 13F-HR |
| Q1 2021 | Mar 31, 2021 | Nov 15, 2022 | 37 | $2.5B | 13F-HR |
| Q4 2020 | Dec 31, 2020 | Nov 15, 2022 | 33 | $2.1B | 13F-HR |
| Q3 2020 | Sep 30, 2020 | Nov 15, 2022 | 26 | $2.1B | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.